This clinical trial focuses on studying the long-term safety of a treatment for Prostate Cancer. The treatment being studied is a medication called Enzalutamide, which is taken as a soft capsule. This study is specifically for individuals who have previously participated in an enzalutamide clinical study and are continuing to benefit from the treatment. The purpose of the study is to gather information on the safety of enzalutamide over an extended period.

Participants in this study will continue to take enzalutamide as they did in their previous study. The study will monitor their health and any side effects they may experience while taking the medication. The study will last for a maximum of 36 months, during which participants will take enzalutamide daily. The study will also involve the use of other medications, such as Abiraterone and Prednisolone, which are also taken orally. These medications are used in combination with enzalutamide to manage prostate cancer.

Throughout the study, participants will be regularly assessed by healthcare professionals to ensure their safety and to determine the ongoing benefits of the treatment. The study aims to provide valuable information on the long-term use of enzalutamide and its effects on individuals with prostate cancer. Participants will be required to follow specific guidelines, such as using birth control methods, to ensure their safety and the integrity of the study results.